Cytokine evaluation in liver cirrhosis and hepatocellular carcinoma

Hepato-Gastroenterology

Volumn 56, Issue 93, 2009, Pages 1105-1110

  Cheng, Ken Sheng ^a   Tang, Hui Ling ^a   Chou, Fu Tsan ^a   Chou, Jen Wei ^a   Hsu, Chang Hu ^a   Yu, Cheng Ju ^a   Kao, Shung Te ^a   Li, Tsai Chung ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Alpha fetoprotein; Hepatocellular carcinoma; Interleukin; Liver cirrhosis; Tumour necrosis factor alpha

Indexed keywords

ALPHA FETOPROTEIN; CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; AGED; ANALYSIS OF VARIANCE; BLOOD; CASE CONTROL STUDY; LIVER TUMOR; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PROSPECTIVE STUDY;

ADULT; AGED; ALPHA-FETOPROTEINS; ANALYSIS OF VARIANCE; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-6; INTERLEUKIN-8; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70350498823     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Ayada M, Ishikawa T, Okumura A, et al.: Alteration of serumcytokine balances among different phases of chronic hepatitis B virus infection. Hepatol Res 2006; 34:214-221.
2. Karrin M: Nuclear factor-kB in cancer development and progression. Nature 2006; 441:431-436.
3. Yang H, Bochetta M, Kroczynska B, et al.: TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 2006; 103:10397-10402. (Pubitemid 44051178)
4. Hussain SP, Hofseth LJ, Harris CC: Radical causes of cancer. Nat Rev Cancer 2003; 3:276-285. (Pubitemid 37328863)
5. Franco A, Guidotti LG, Hobbs MV, et al.: Pathogenesis effector function of CD4-positive T helper 1 cells in hepatitis B virus transgenic mice. J Immunol 1997; 159:2001-2008. (Pubitemid 127484191)
6. Deviere J, Content J, Denys C, et al.: High interleukin-6 serum levels and increased production by leucocytes in alcohoUc liver cirrhosis. Correlation with IgA serum levels and lymphokines production. Clinical and Experimental Immunology 1989; 77:221-225. (Pubitemid 19206491)
7. Malaguamera M, Di Fazio I, Romeo MA, et al.: Elevation of interleukin 6 levels in patients with chronic hepatitis due to hepatitis C virus. J Gastroenterol 1997; 32:211-215. (Pubitemid 27223085)
8. Hodge DR, Hurt EM, Farrar WL: The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005; 41:2502-2512. (Pubitemid 41540626)
9. Chau GY, Wu CW, Lui WY, et al.: Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg 2000; 231:552-558.
10. Fortis C, Foppoli M, Gianotti L, et al.: Increased interleukin-10 serum levels in patients with solid tumours. Cancer Lett 1996; 104:1-5. (Pubitemid 26154004)
11. Zhang T, Kawakami K, Qureshi MH, et al.: Interleukin-12 (IL-12) and IL-18 synergistically induce the fungicidal activity of murine peritoneal exudate cells against Cryptococcus neoformans through production of gamma interferon by natural killer cells. Infect Immun 1997; 65:3594-3599. (Pubitemid 27398112)
12. Dao T, Mehal WZ, Cripe IN: IL-18 augments perforin-dependent cytotoxicity of liver NK-T cells. J Immunol 1998; 161:2217-2222. (Pubitemid 28397032)
13. Ludwiczek O, Kaser A, Novidk D, Dinarello CA, Rubinstein M, Vogel W, Tilg H: Elevated systemic levels of free interleukin-18 (IL-18) in patients with Crohn's disease. J Clin Immunol 2000: 22;331-337.
14. Lee MO, Choi YH, Shin EC, et al.: Hepatitis B virus X protein induced expression of interleukin 18 (IL-18): A potential mechanism for liver injury caused by hepatitis B virus (HBV) infection. J Hepatol 2002; 37:380-386.
15. McGuinness PH, Painter D, Davies S, McCaughan GW: Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut 2000; 46:260-269. (Pubitemid 30305855)
16. Hsia C-Y, Huo T-I, Chiang S-Y, et al.: Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. EJSO 2007; 33:208-212. (Pubitemid 46336558)
17. Chia CS, Ban K, Ithnin H, et al.: Expression of interleukin-18, interferon-γ and interleukin-10 in hepatocellular carcinoma. Immunology Letters 2002; 84:163-172. (Pubitemid 35292375)
18. Bolondi L, Gaiani S, Celli N, et al.: Characterization of smaU nodules in cirrhosis by assessment of vascularity: The problem of hypovascular hepatocellular carcinoma. Hepatology 2005; 42:27-34. (Pubitemid 40911308)
19. El-Kady M, Lotfy M, Badra G, El-Masry S, Waked I: Interleukin (IL)-4, IL-10, IL-18 and IFN-γ cytokines pattern in patients with combined hepatitis C virus and Schistosoma mansoni infections. Scand J Immunol 2005; 61:87-91. (Pubitemid 40188352)
20. Yumoto E, Higashi T, Nouso K, et al.: Serum gamma-interferon-inducing factor (IL-18) and IL-10 levels in patients with acute hepatitis and fulminant hepatic failure. J Gastroenterol Hepatol 2002; 17:285-294. (Pubitemid 34534101)
21. Tangkijvanich P, Thong-Ngam D, Mahachai V, et al.: Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma. World J Gastroenterol 2007; 13:4345-4349. (Pubitemid 47377141)
22. Tsuboi K, Miyazaki T, Nakajima M, et al.: Serum interleukin-12 and interleukin-18 levels as a tumor marker in patients with esophageal carcinoma. Cancer Lett 2004; 205:207-214. (Pubitemid 38230128)
23. Pages F, Berger A, Henglein B, et al.: Modulation of interleukin-18 expression in human colon carcinoma: consequences for tumor immune surveillance. Int J Cancer 1999; 84: 326-330. (Pubitemid 29256763)
24. Takubo T, Okura H, Kumura T, et al.: Human IL-18 bioactivity in hematological malignancies with highly elevated serum IL-18 levels. Acta Haematol 2000; 103:162-164.
25. Gunel N, Coskun U, Sancak B, et al.: Prognostic value of serum IL-18 and nitric oxide activity in breast cancer patients at operable stage. Am J CUn Oncol 2003; 26: 416-421. (Pubitemid 36962090)
26. Kawabata T, Ichikura T, Majima T, et al.: Preoperative serum interleukin-18 level as a postoperative prognostic marker in patients with gastric carcinoma. Cancer 2001; 92: 2050-2055. (Pubitemid 32973313)
27. Kiki I, Yilmaz O, Erdem F, et al.: Tumor necrosis factor-alpha levels in hepatitis B virus-related chronic active hepatitis and liver cirrhosis and its relationship to Knodell and Child-Pugh scores. Int J Clin Pract 2007; 60:1075-1079.
28. Zhang W, Yue B, Wang GQ, Lu SL: Serum and ascites levels of macrophage migration inhibitory factor, TNF-alpha and 11-6 in patients with chronic virus hepatitis B and cirrhosis. Hepatobiliary Pancreatic Dis Int 2002; 1:577-580. (Pubitemid 36748246)
29. Tilg H, Wilmer A, Vogel W, Herold M, Nolchen B, Judmaier G, Huber C: Serum levels of cytokines in chronic liver diseases. Gastroenterol 1992;103:264-274.